Cowen Increases Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $85.00

Share on StockTwits

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective lifted by analysts at Cowen from $70.00 to $85.00 in a note issued to investors on Thursday, The Fly reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. Cowen’s target price would suggest a potential downside of 1.20% from the stock’s current price.

A number of other research firms have also recently commented on TNDM. Raymond James initiated coverage on Tandem Diabetes Care in a research note on Wednesday, February 5th. They set an “outperform” rating and a $85.00 target price on the stock. Robert W. Baird lowered Tandem Diabetes Care from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $71.00 to $75.00 in a report on Tuesday, February 4th. ValuEngine raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Tuesday, February 4th. Guggenheim started coverage on Tandem Diabetes Care in a report on Thursday, October 17th. They issued a “buy” rating and a $76.00 price objective for the company. Finally, BidaskClub raised Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $79.79.

NASDAQ TNDM opened at $86.03 on Thursday. The stock has a market capitalization of $5.08 billion, a price-to-earnings ratio of -172.06 and a beta of 0.08. Tandem Diabetes Care has a one year low of $47.36 and a one year high of $87.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.46 and a quick ratio of 2.05. The business’s fifty day moving average is $69.23 and its 200-day moving average is $64.48.

In other Tandem Diabetes Care news, CFO Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $70.35, for a total transaction of $703,500.00. Following the completion of the transaction, the chief financial officer now owns 13,265 shares of the company’s stock, valued at approximately $933,192.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John F. Sheridan sold 462 shares of Tandem Diabetes Care stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $70.00, for a total value of $32,340.00. Following the transaction, the chief executive officer now directly owns 2,963 shares of the company’s stock, valued at approximately $207,410. The disclosure for this sale can be found here. In the last three months, insiders sold 319,778 shares of company stock valued at $20,871,101. 6.90% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the business. CWM LLC grew its holdings in Tandem Diabetes Care by 393.5% during the 4th quarter. CWM LLC now owns 528 shares of the medical device company’s stock valued at $31,000 after buying an additional 421 shares in the last quarter. First Quadrant L P CA purchased a new position in Tandem Diabetes Care during the 3rd quarter valued at about $34,000. TRUE Private Wealth Advisors purchased a new position in Tandem Diabetes Care during the 4th quarter valued at about $45,000. Sowell Financial Services LLC purchased a new position in Tandem Diabetes Care during the 4th quarter valued at about $54,000. Finally, US Bancorp DE grew its holdings in Tandem Diabetes Care by 101.0% during the 4th quarter. US Bancorp DE now owns 1,164 shares of the medical device company’s stock valued at $70,000 after buying an additional 585 shares in the last quarter. 82.96% of the stock is owned by institutional investors and hedge funds.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Story: Why is the price-sales ratio important?

The Fly

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.